spacer
home > pmps > autumn 2008 > a revolution in aseptic filling
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

A Revolution in Aseptic Filling

The aseptic filling of injectable drugs has always been a challenge for the pharmaceutical industry. Contamination accidents, despite being rare, are still recorded among the 20 billion injections and infusions made every year in the world.

In a recent market study, six per cent of hospital professionals in Europe and the US reported that they have already faced at least one case of contaminated vials. In recent years, the authorities have taken a radical turn to strongly support the most advanced aseptic filling technologies, such as the use of isolators, whereas the use of classical processes in an Iso 5/Grade A cleanroom are more and more questioned, as the risks caused by proximity of operators to the open containers becomes evident...


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Benoоt Verjans has a PhD degree in Biochemistry and a MBA from the University of Brussels. He has developed a post-doctoral programme at the University of Cambridge (UK). He worked at UCB Pharma in International Marketing, at McKinsey and Co as a consultant, in the pharma sector (marketing, supply chain and licensing projects), and as CEO of 4AZA Bioscience, a start-up from the University of Leuven developing new immuno-modulating drugs. He is currently Commercial Director of Aseptic Technologies, responsible for developing the sales of closed vial technology worldwide. He is on the Editorial Board of Pharmaceutical Technology Europe and a member of ISPE.
spacer
Benoоt Verjans
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Companyís novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

DIA 2019 Global Annual Meeting

23-27 June 2019, San Diego Convention Center

DIA 2019 is more than just a meeting: itís where brilliant minds come together to create solutions. Thousands of global innovators will convene to engage in discussions on todayís hottest topics in the life sciences field, propose ways to combat daily challenges, and network to create lasting connections.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement